HC Wainwright Issues Negative Forecast for DRUG Earnings

Bright Minds Biosciences Inc. (NASDAQ:DRUG) – Equities researchers at HC Wainwright dropped their Q3 2025 earnings estimates for Bright Minds Biosciences in a research report issued to clients and investors on Wednesday, February 19th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.73) per share for the quarter, down from their previous estimate of ($0.72). HC Wainwright has a “Buy” rating and a $85.00 price objective on the stock. The consensus estimate for Bright Minds Biosciences’ current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Bright Minds Biosciences’ Q4 2025 earnings at ($0.88) EPS, FY2025 earnings at ($2.30) EPS, Q1 2026 earnings at ($0.96) EPS, Q2 2026 earnings at ($1.27) EPS, Q3 2026 earnings at ($1.54) EPS, Q4 2026 earnings at ($1.79) EPS, FY2026 earnings at ($5.63) EPS, FY2027 earnings at ($5.72) EPS, FY2028 earnings at ($5.80) EPS and FY2029 earnings at ($1.70) EPS.

DRUG has been the topic of several other research reports. Piper Sandler initiated coverage on Bright Minds Biosciences in a report on Thursday, January 23rd. They set an “overweight” rating and a $93.00 price objective on the stock. Cantor Fitzgerald initiated coverage on Bright Minds Biosciences in a report on Friday, January 10th. They set an “overweight” rating on the stock. Robert W. Baird initiated coverage on Bright Minds Biosciences in a report on Monday, November 25th. They set an “outperform” rating and a $75.00 price objective on the stock. Finally, Baird R W upgraded Bright Minds Biosciences to a “strong-buy” rating in a report on Monday, November 25th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Bright Minds Biosciences presently has an average rating of “Buy” and an average target price of $84.33.

Bright Minds Biosciences Trading Down 0.4 %

Shares of Bright Minds Biosciences stock opened at $35.99 on Friday. The company’s 50-day moving average price is $37.98 and its two-hundred day moving average price is $26.66. Bright Minds Biosciences has a 52 week low of $0.93 and a 52 week high of $79.02. The stock has a market cap of $253.37 million, a PE ratio of -211.69 and a beta of -6.71.

Bright Minds Biosciences (NASDAQ:DRUG) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.23) by $0.24.

Hedge Funds Weigh In On Bright Minds Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE purchased a new position in Bright Minds Biosciences during the 4th quarter valued at about $173,000. Jane Street Group LLC purchased a new position in Bright Minds Biosciences during the 4th quarter valued at about $238,000. Atika Capital Management LLC purchased a new position in Bright Minds Biosciences during the 4th quarter valued at about $540,000. Millennium Management LLC purchased a new position in Bright Minds Biosciences during the 4th quarter valued at about $1,454,000. Finally, Boothbay Fund Management LLC purchased a new position in Bright Minds Biosciences during the 4th quarter valued at about $1,606,000. Hedge funds and other institutional investors own 40.52% of the company’s stock.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.